SLC5A2 and familial primary hypomagnesemia: Given the refractory nature of her hypomagnesemia and persistent symptoms, an SGLT2 inhibitor was initiated, resulting in significant clinical and biochemical improvement, with serum magnesium levels rising to 2.3 mg/dL (Figure 1(b)).